Biotheranostics, Inc. today announced new data from two new studies further demonstrating the importance of BCI in clinical practice. The studies are being presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago this week.
Trice Medical announced today that it closed a $19.3 million Series C financing and will use the proceeds to accelerate and expand the company's U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. Smith & Nephew (LSE:SN, NYSE: SNN) has taken a minority stake joining a consortium of current investors including HealthQuest.
Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners.
Friendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma (UM). Evidence Street provides objective information to healthcare and managed care professionals based on clinical and scientific evidence and evaluates whether a technology could improve net health outcomes
Vesey Street Capital Partners, LLC (VSCP) today announced the completed recapitalization of HealthChannels (parent company of ScribeAmerica), a healthcare services organization with a full suite of solutions that enhances provider productivity, streamlines clerical processes and improves health outcomes. With 13,000 employees across 50 states and three countries, HealthChannels is uniquely positioned to help providers meet increased demands around mission-critical activities ranging from electronic medical records documentation to patient navigation, medical billing and coding. HealthQuest Capital and Heritage Group joined Vesey Street in the financing.
Avizia, the leading end to end telehealth solution provider, today announced the completion of its Series A financing totaling $17 million. The company raised an additional $6 million to supplement the initial $11 million, which was announced in July 2016. HealthQuest Capital led the additional round which included investment from strategic partner NewYork-Presbyterian.
Trice Medical announced today that it received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for mi-eye 2, a disposable needle with a fully integrated camera that enables physicians to use advanced diagnostic imaging to visualize joint injuries in their clinic.
Magnolia Medical Technologies, developer of the SteriPath® blood collection system and leader in improving the quality and accuracy of in-vitro diagnostic test results, today announced the closing of the company's $13.8 million Series B financing led by HealthQuest Capital. In conjunction with the financing, Garheng Kong, M.D., Ph.D., founder and managing partner of HealthQuest Capital will join the company's board.
VirMedica, the leader in providing e-access and specialty pharmacy technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of three new executives to the Company's senior leadership team. John J. Arcari has been appointed to chief financial officer (CFO) and will oversee the Company's financial operations. Richard Deyermond joins the company as vice president of client services and will lead teams engaged in the delivery of VirMedica's technology solutions. As the vice president of engineering, Elizabeth Ricci will focus on building out the Company's technology suite.
VirMedica, the leader in providing eACCESS technology solutions designed to expedite patient access to biopharmaceutical products, today announced that its Board of Directors has appointed Philip Lee as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately.
Trice Medical, an early stage medical device company, announced the appointment of William Hawkins to the company's board of directors, effective April 1, 2016. Hawkins joins a distinguished Board of proven industry leaders in their pursuit to revolutionize arthroscopic diagnostics. Mr. Hawkins is a renowned healthcare executive with diverse experience in healthcare delivery, innovation, and entrepreneurship.
HealthQuest Capital announced the closing of HealthQuest Capital II, LP, at the hard cap of $225 million and in excess of the initial fund target of $175 million. Investors in the fund include endowments, family offices, foundations, fund-of-funds, pension funds, and global healthcare organizations.
Read More →
Spirox Inc., a privately held medical device company, announced today the closing of a $45 million Series C round of financing led by KKR, a leading global investment firm. Also participating in the financing is new investor HealthQuest Capital along with major existing shareholders Aisling Capital, Aperture Venture Partners and Venrock.
Read More →
Orlando, Florida-based Vestagen Technical Textiles Inc, a medical technology company developing apparel for healthcare applications, raised $7 million in financing. Advent Life Sciences and HealthQuest Capital led the round, which was a planned extension of the company’s previous financing. Vestagen also named Bill Bold as chief executive officer. Bold replaces Dale Pfost, PhD, who was serving as interim CEO and remains chairman of the board.
Read More →
BioTheranostics, a leader in molecular diagnostics for cancer, today announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, bioTheranostics will be spun out from bioMérieux, which will remain a minority shareholder, and operate as an independent company.
Read More →
Industry publication, The MedTech Strategist, interviewed Garheng Kong about HealthQuest and the origins of the firm.
Read More →
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data from a new test discovered by the Company to assess the risk of cancer recurrence in patients diagnosed with soft tissue sarcomas (STS). Results were presented in a poster session at the Connective Tissue Oncology Society Annual Meeting, November 4-7, 2015 in Salt Lake City.
Read More →